Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...

CAMBRIDGE, MA / ACCESS Newswire / May 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2025. "In the first quarter, we ...

Why it matters: With $8.4 billion in cash left at the end of the quarter, investors are closely watching Moderna's strategy for focusing its remaining covid vaccine profits from the pandemic on ...

Researchers from vaccine-maker Moderna reported in a study published Wednesday that the new combo shot generated a stronger immune response against COVID-19 and most strains of flu than existing ...